LLY vs. NVO
Compare and contrast key facts about Eli Lilly and Company (LLY) and Novo Nordisk A/S (NVO).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: LLY or NVO.
Correlation
The correlation between LLY and NVO is 0.24, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Performance
LLY vs. NVO - Performance Comparison
Key characteristics
LLY:
0.12
NVO:
-1.18
LLY:
0.40
NVO:
-1.72
LLY:
1.05
NVO:
0.77
LLY:
0.16
NVO:
-0.86
LLY:
0.35
NVO:
-1.74
LLY:
11.17%
NVO:
26.39%
LLY:
31.76%
NVO:
38.77%
LLY:
-68.27%
NVO:
-71.29%
LLY:
-17.53%
NVO:
-53.42%
Fundamentals
LLY:
$734.75B
NVO:
$309.27B
LLY:
$11.68
NVO:
$3.29
LLY:
70.05
NVO:
20.74
LLY:
1.18
NVO:
1.06
LLY:
$36.27B
NVO:
$225.05B
LLY:
$29.53B
NVO:
$190.45B
LLY:
$12.51B
NVO:
$113.24B
Returns By Period
In the year-to-date period, LLY achieves a 2.39% return, which is significantly higher than NVO's -20.74% return. Over the past 10 years, LLY has outperformed NVO with an annualized return of 29.61%, while NVO has yielded a comparatively lower 11.49% annualized return.
LLY
2.39%
-13.39%
-10.59%
2.35%
43.29%
29.61%
NVO
-20.74%
-22.08%
-40.75%
-46.11%
19.54%
11.49%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
LLY vs. NVO — Risk-Adjusted Performance Rank
LLY
NVO
LLY vs. NVO - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Eli Lilly and Company (LLY) and Novo Nordisk A/S (NVO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
LLY vs. NVO - Dividend Comparison
LLY's dividend yield for the trailing twelve months is around 0.68%, less than NVO's 2.40% yield.
| TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
LLY Eli Lilly and Company | 0.68% | 0.67% | 0.78% | 1.07% | 1.23% | 1.75% | 1.96% | 1.95% | 2.46% | 2.77% | 2.37% | 2.84% |
NVO Novo Nordisk A/S | 2.40% | 1.68% | 1.00% | 1.20% | 1.34% | 1.86% | 2.14% | 2.47% | 2.12% | 3.93% | 1.31% | 1.96% |
Drawdowns
LLY vs. NVO - Drawdown Comparison
The maximum LLY drawdown since its inception was -68.27%, roughly equal to the maximum NVO drawdown of -71.29%. Use the drawdown chart below to compare losses from any high point for LLY and NVO. For additional features, visit the drawdowns tool.
Volatility
LLY vs. NVO - Volatility Comparison
The current volatility for Eli Lilly and Company (LLY) is 10.00%, while Novo Nordisk A/S (NVO) has a volatility of 12.78%. This indicates that LLY experiences smaller price fluctuations and is considered to be less risky than NVO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Financials
LLY vs. NVO - Financials Comparison
This section allows you to compare key financial metrics between Eli Lilly and Company and Novo Nordisk A/S. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities